Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants
Cardiology in the Young · 2025-01 · 35 (1) · 93-101
DOI: 10.1017/s1047951124025976 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cardiology in the Young, online erschienen am 16.10.2024. Verfasst von Karan R Kumar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Vasodilator Agents, Critical Illness, Hypertension, Pulmonary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
New drugs to target different pathways in pulmonary hypertension has resulted in increased combination therapy, but details of this use in infants are not well described. In this large multicenter database study, we describe the pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.
Methods
We identified inborn infants discharged home from a Pediatrix neonatal ICU from 1997 to 2020 exposed to inhaled nitric oxide, sildenafil, epoprostenol, or bosentan for greater than two consecutive days. We compared clinical variables and drug utilisation between infants receiving simultaneous combination and monotherapy. We reported each combination’s frequency, timing, and duration and graphically represented drug use over time.
Results
Of the 7681 infants that met inclusion criteria, 664 (9%) received combination therapy. These infants had a lower median gestational age and birth weight, were more likely to have cardiac and pulmonary anomalies, receive cardiorespiratory support, and had higher in-hospital mortality than those receiving monotherapy. Inhaled nitric oxide and sildenafil were most frequently used, and utilisation of combination and monotherapy for all drugs increased over time. Inhaled nitric oxide and epoprostenol were used in infants with a higher gestational age, earlier postnatal age, and shorter duration than sildenafil and bosentan. Dual therapy with inhaled nitric oxide and sildenafil was the most common combination therapy.
Conclusion
Our study revealed an increased use of combination pulmonary vasodilator therapy, favouring inhaled nitric oxide and sildenafil, yet with considerable practice variation. Further research is needed to determine the optimal combination, sequence, dosing, and disease-specific indications for combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
- University of North Carolina School of Medicine, Chapel Hill, NC, USA.
- Pediatrix Center for Research, Education, Quality, and Safety, Sunrise, FL, USA.
- Children's Intensive Care Unit, KK Women's and Children's Hospital, Singapore, Singapore.
- Paediatrics Academic Clinical Programme, Duke-NUS School of Medicine, Singapore, Singapore.
ORCID-Profile: Karan R Kumar, Christoph P Hornik
Förderung
- NICHD NIH HHS
- NCATS NIH HHS
Zitieren
APA
Kumar, K. R., Ciociola, E. C., Skinner, K. R., Dixit, G. M., Alvarez, S., Benjamin, E. K., Faulkner, J. C., Greenberg, R. G., Clark, R. H., Benjamin, D. K., Hornik, C. P., & Lee, J. H. (2025). Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. Cardiology in the Young, 35(1), 93-101. https://doi.org/10.1017/s1047951124025976
Vancouver
Kumar KR, Ciociola EC, Skinner KR, Dixit GM, Alvarez S, Benjamin EK, et al. Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. Cardiology in the Young. 2025;35(1):93-101. doi:10.1017/s1047951124025976
BibTeX
@article{Kumar2025,
author = {Kumar, Karan R and Ciociola, Elizabeth C and Skinner, Kayla R and Dixit, Gargi M and Alvarez, Sunshine and Benjamin, Elijah K and Faulkner, Jeffrey C and Greenberg, Rachel G and Clark, Reese H and Benjamin, Daniel K and Hornik, Christoph P and Lee, Jan Hau},
title = {Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants},
journal = {Cardiology in the Young},
year = {2025},
volume = {35},
number = {1},
pages = {93--101},
doi = {10.1017/s1047951124025976}
}
EUVIMED